Table 2.

Match-Eligible Population

Age, Months	Carriage Endpoint	Vaccine	Dosing Compared	Bedouin Children		Jewish Children
			Exposure vs Reference	Eligible Case Population	Match-Eligible Non-case Population	Eligible Case Population	Match-Eligible Non-case Population
				n	n	n	n
≤12	PCV7 serotypes	PCV7/13	1p vs 0p	62	535	15	83
			2p vs 0p	119	985	30	210
			1p vs 2p	47	379	14	99
		PCV7	1p vs 0p	47	375	11	47
			2p vs 0p	54	409	11	73
			1p vs 2p	43	192	10	49
		PCV13	1p vs 0p	44	453	10	68
			2p vs 0p	54	494	16	97
			1p vs 2p	40	362	14	99
	PCV13 serotypes	PCV13	1p vs 0p	101	637	19	131
			2p vs 0p	113	742	28	172
			1p vs 2p	94	622	23	164
	+6PCV13 serotypes	PCV13	1p vs 0p	57	552	9	71
			2p vs 0p	59	548	12	78
			1p vs 2p	54	435	9	73
13–25	PCV7 serotypes	PCV7/13	0p+0p vs 2p+1b	23	112	17	121
			2p+0b vs 2p+1b	31	213	13	137
			1p+1b vs 2p+1b	19	112	13	116
			0p+2b vs 2p+1b	21	115	14	124
		PCV7	0p+0p vs 2p+1b	10	23	6	12
			2p+0b vs 2p+1b	9	36	1	6
			1p+1b vs 2p+1b	5	21	2	7
			0p+2b vs 2p+1b	8	33	3	16
		PCV13	0p+0p vs 2p+1b	18	90	15	100
			2p+0b vs 2p+1b	18	141	11	115
			1p+1b vs 2p+1b	12	84	10	94
			0p+2b vs 2p+1b	11	75	10	94
	PCV13 serotypes	PCV13	0p+0p vs 2p+1b	31	163	18	114
			2p+0b vs 2p+1b	33	218	15	141
			1p+1b vs 2p+1b	24	147	12	103
			0p+2b vs 2p+1b	23	143	13	108
	+6PCV13 serotypes	PCV13	0p+0p vs 2p+1b	13	96	3	14
			2p+0b vs 2p+1b	15	120	4	26
			1p+1b vs 2p+1b	12	89	2	9
			0p+2b vs 2p+1b	12	87	3	19
25–59	PCV7 serotypes	PCV7/13	0p+0p vs 2p+1b	49	272	31	177
			2p+0b vs 2p+1b	18	148	10	86
			1p+1b vs 2p+1b	17	144	9	79
			0p+2b vs 2p+1b	21	155	10	81
		PCV7	0p+0p vs 2p+1b	35	146	23	104
			2p+0b vs 2p+1b	4	11	1	4
			1p+1b vs 2p+1b	2	6	1	3
			0p+2b vs 2p+1b	6	20	2	7
		PCV13	0p+0p vs 2p+1b	46	246	26	151
			2p+0b vs 2p+1b	13	111	5	52
			1p+1b vs 2p+1b	13	109	4	47
			0p+2b vs 2p+1b	14	110	4	45
	PCV13 serotypes	PCV13	0p+0p vs 2p+1b	66	288	52	220
			2p+0b vs 2p+1b	16	138	13	100
			1p+1b vs 2p+1b	16	135	11	95
			0p+2b vs 2p+1b	17	136	11	91
	+6PCV13 serotypes	PCV13	0p+0p vs 2p+1b	20	148	26	156
			2p+0b vs 2p+1b	3	40	8	71
			1p+1b vs 2p+1b	3	38	7	67
			0p+2b vs 2p+1b	3	37	7	64

Data indicate numbers of all children available for each comparison (including children eligible for inclusion as cases for whom matched controls, defined irrespective of colonization status, could be identified). As controls could include children carrying vaccine-serotype pneumococci (here listed as “case-eligible” children), the numbers of cases and controls in each analysis iteration do not necessarily correspond to the column entries.

Abbreviations: b, booster; p, primary; +6PCV13, the 6 serotypes contained in PCV13 and not PCV7; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.